Tresiba Cost in Pennsylvania 2026

What Is the Actual Price of Tresiba in Pennsylvania in 2026?

The Novo Nordisk manufacturer list price for Tresiba sits near $510 per month in 2026, but almost no Pennsylvania patient pays that number. With a GoodRx or similar pharmacy discount card, the real out-of-pocket cash price at Pennsylvania retail pharmacies averages approximately $35 per month. Patients with commercial insurance who qualify for the Novo Nordisk My$99Insulin program pay no more than $99 per fill, and patients on PA Medicaid may pay $0 to $3 in copays after prior-authorization approval.

The $510 figure represents the wholesale acquisition cost before any rebates, discounts, or assistance programs are applied. Pharmacy benefit managers, state Medicaid programs, and manufacturer savings programs all negotiate prices below that ceiling. A 2023 analysis published in JAMA found that the net price paid for insulin (after rebates) was often 40 to 70% below the list price across commercial payers, meaning the real cost of Tresiba for insured Pennsylvania patients is substantially lower than the sticker price. [1]

Pennsylvania also benefits from the federal Inflation Reduction Act cap of $35 per month on insulin for Medicare Part D beneficiaries beginning January 2023, which applies to brand insulins including Tresiba for all Pennsylvania Medicare enrollees. [2] The American Diabetes Association published updated insulin access guidance in 2024 noting that "cost barriers to insulin have declined materially for Medicare patients since the $35 monthly cap took effect." [3]

Novo Nordisk publishes its net and list pricing data publicly at novonordisk-us.com, and the FDA maintains the official prescribing label. [4]

Does Pennsylvania Medicaid Cover Tresiba?

Pennsylvania Medicaid (called Medical Assistance) covers insulin degludec for both type 1 and type 2 diabetes, but prior authorization is required on most managed-care formularies. The PA Department of Human Services publishes the preferred drug list for each Community HealthChoices and HealthChoices managed-care organization, and Tresiba appears as a covered non-preferred brand on most of those lists. [5]

Prior authorization criteria typically require documentation of at least one trial of a preferred formulary basal insulin (usually insulin glargine U-100 or biosimilar glargine) plus a clinical reason for switching. Acceptable reasons include hypoglycemia on NPH or glargine, adherence difficulties related to strict timing requirements, or documented provider preference for degludec's longer and flatter pharmacodynamic profile. The FDA label for Tresiba notes that insulin degludec has a duration of action exceeding 42 hours and a half-life of approximately 25 hours, providing a more stable glucose-lowering effect than insulin glargine in clinical testing. [4]

The DEVOTE trial (N=7,637, NEJM 2017) compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78, 1.06, P<0.001 for non-inferiority). Severe hypoglycemia rates were 40% lower with degludec (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). [6] That hypoglycemia reduction is among the strongest documented clinical arguments for PA Medicaid prior-authorization approval when a patient has experienced recurrent lows on another basal insulin.

For Medicaid fee-for-service enrollees (a smaller portion of PA's Medicaid population), the PA DHS Drug Formulary PDL lists insulin degludec under the "Antidiabetic Agents" section with a PA requirement. Prescribers submitting a PA for a fee-for-service patient should use the HealthChoices Pharmacy Prior Authorization Request form and include the patient's A1C, current insulin regimen, and hypoglycemia documentation. [5]

Is Compounded Insulin Degludec Legal in Pennsylvania?

Compounded insulin degludec from a state-licensed 503A compounding pharmacy is legal in Pennsylvania. A 503A pharmacy compounds medications for individual patients based on a valid prescription, and Pennsylvania licenses these pharmacies through the Pennsylvania State Board of Pharmacy. [7]

503A compounded insulin degludec is not FDA-approved and is not identical to brand Tresiba. The FDA does not review compounded formulations for safety, efficacy, or potency equivalence. The American Diabetes Association's 2024 Standards of Care state: "Compounded insulins are not FDA-approved, and their safety, efficacy, and potency are not established; patients should be informed of these limitations." [3] Prescribers at HealthRX disclose these facts to every patient before writing a compounded insulin prescription.

From a cost standpoint, compounded insulin degludec from a 503A pharmacy in Pennsylvania can cost $0 to a nominal dispensing fee depending on the pharmacy's pricing model, making it the least expensive access pathway for uninsured patients. The pharmacokinetic profile of a compounded preparation may differ from the commercially manufactured Tresiba FlexTouch pen, so clinical monitoring including self-monitored blood glucose and periodic A1C testing is advisable when a patient switches formulations. [8]

The FDA has not placed insulin degludec on its "difficult to compound" list as of mid-2025, so 503A pharmacies may compound it legally without restriction at the federal level. [9] Pennsylvania state law imposes no additional prohibition beyond the federal 503A framework. [7]

HealthRX Compounded Insulin Decision Framework for Pennsylvania Patients

Use this three-gate check before ordering compounded insulin degludec in PA:

1. Gate 1: Insurance status. If the patient has active PA Medicaid or commercial insurance with a formulary path to Tresiba, pursue prior authorization before compounding.
2. Gate 2: Clinical documentation. If prior authorization is denied or the patient is uninsured, document A1C, current regimen, and hypoglycemia history to support medical necessity.
3. Gate 3: Monitoring plan. Confirm the patient has a blood glucose monitoring device and will schedule a follow-up A1C at 3 months to verify glycemic equivalence with the new formulation.

Can Pennsylvania Patients Get Tresiba via Telehealth?

Pennsylvania fully permits telehealth prescribing of controlled and non-controlled prescription medications including insulin. Tresiba is not a controlled substance, so no DEA-registration restriction applies. Pennsylvania law (Act 86 of 2020) codified audio-visual telehealth as a permanent modality for prescribing after the COVID-19 public health emergency, and the Pennsylvania Medical Practice Act was amended to allow audio-only prescribing for established patients in certain circumstances. [10]

A HealthRX clinician licensed in Pennsylvania can conduct a synchronous video visit, review the patient's diabetes history and current glucose logs, and issue a Tresiba prescription to a Pennsylvania pharmacy within a single encounter. The prescription can be sent electronically to any Pennsylvania retail pharmacy or to a mail-order pharmacy serving Pennsylvania. No in-person visit is required for a new Tresiba prescription for type 2 diabetes when the clinical record supports the diagnosis and dosing. For type 1 diabetes patients new to a telehealth practice, most Pennsylvania telehealth providers require one comprehensive visit with upload of recent lab work (A1C, basic metabolic panel, and a current continuous glucose monitor or blood glucose log) before initiating or continuing a basal insulin prescription.

The CDC's 2023 National Diabetes Statistics Report shows that 11.6% of the U.S. adult population has diagnosed diabetes and that insulin use is highest in patients with type 1 and long-duration type 2 diabetes, many of whom benefit from prescription continuity via telehealth when in-person access is limited. [11]

Which Insurance Plans Cover Tresiba in Pennsylvania?

Most major commercial insurance plans operating in Pennsylvania include insulin degludec on their formularies, though tier placement varies. The following coverage patterns apply in 2026.

Blue Cross Blue Shield of Pennsylvania (Independence Blue Cross, Highmark). Both Highmark and Independence Blue Cross place Tresiba on Tier 3 (non-preferred brand) in most employer and ACA marketplace plans. Tier 3 copays in Pennsylvania typically range from $60 to $150 per fill depending on the plan design. Prior authorization may apply if insulin glargine is on Tier 2. [12]

Aetna and Cigna plans in Pennsylvania. Aetna and Cigna both list insulin degludec on their commercial formularies as non-preferred brands with PA requirements in most plans. The Novo Nordisk savings card can reduce the post-adjudication copay. [12]

Medicare Part D in Pennsylvania. All Part D plans must cover at least one basal insulin. Tresiba appears on select Part D formularies; the $35/month cap applies regardless of tier or deductible phase for insulin-covered enrollees. Patients should use Medicare's Plan Finder at medicare.gov to verify their specific plan covers Tresiba before filling. [2]

PA CHIP (Children's Health Insurance Program). CHIP in Pennsylvania covers insulin degludec with similar prior-authorization criteria to Medicaid. [5]

A 2022 Health Affairs analysis found that formulary restrictions on newer basal insulins including insulin degludec affected 38% of commercially insured patients at the time of a new prescription, highlighting the frequency with which prior-authorization appeals become necessary. [13]

How the Novo Nordisk Savings Card Works in Pennsylvania

The Novo Nordisk My$99Insulin program is available to commercially insured Pennsylvania patients who meet eligibility criteria. The program caps the monthly out-of-pocket cost of Tresiba at $99 for patients with private insurance. Patients without insurance are not eligible for the savings card but may access the Novo Nordisk Patient Assistance Program (NovoCare), which provides Tresiba at no cost to qualifying low-income uninsured individuals. [14]

To use the savings card in Pennsylvania:

1. Download or activate the card at novonordisk-us.com or through the NovoCare portal.
2. Present the card at a Pennsylvania retail pharmacy alongside the prescription.
3. The pharmacy adjudicates the commercial insurance claim first, then applies the savings card to reduce the remaining copay.

The card does not work for patients on federal or state government insurance programs including Medicare, Medicaid, CHIP, or TRICARE. Pennsylvania patients on those programs should pursue the Medicaid prior-authorization route or the NovoCare Patient Assistance Program instead. [14]

The FDA reviewed insulin degludec's prescribing label and confirmed the approved dosing range of 0.1 to 0.2 units/kg once daily for type 2 diabetes insulin-naive patients, with dose titration based on fasting glucose targets. [4] Confirming correct dosing with a prescriber before initiating the savings-card program ensures the fill quantity aligns with the covered supply.

What Is the Cheapest Way to Get Tresiba in Pennsylvania?

The least expensive access paths rank roughly as follows for a Pennsylvania patient in 2026.

Path 1: PA Medicaid with PA approval. Copay is $0 to $3 per fill. This requires prior authorization but is the lowest-cost option for eligible patients. [5]

Path 2: NovoCare Patient Assistance Program (uninsured, low income). Tresiba at $0 for qualifying patients. Income thresholds and application process are available at novonordisk-us.com. [14]

Path 3: Pharmacy discount card (uninsured, not low-income). GoodRx, RxSaver, or similar cards bring the Pennsylvania retail cash price to approximately $35 per month at major chains including CVS, Rite Aid, and Giant/Stop and Shop pharmacy locations. [15]

Path 4: Novo Nordisk savings card (commercially insured). Reduces copay to $99/month or less. [14]

Path 5: Medicare Part D with $35 cap. All Medicare Part D enrollees pay no more than $35 per month for covered insulins including Tresiba. [2]

Path 6: Compounded insulin degludec from a 503A pharmacy. Cost is $0 to minimal dispensing fee in Pennsylvania, but the FDA has not approved the compounded formulation and clinical equivalence is not guaranteed. [9]

Path 1 and Path 2 represent the lowest absolute costs. Patients not on Medicaid and not low-income should start with a pharmacy discount card (Path 3) while their prescriber submits any applicable prior authorization to commercial insurance.

Clinical Evidence Supporting Insulin Degludec

Understanding why Tresiba warrants its cost relative to older basal insulins requires a look at the clinical record. The DEVOTE trial (N=7,637) is the largest cardiovascular outcomes trial of insulin degludec to date. Published in the New England Journal of Medicine in 2017, DEVOTE showed insulin degludec was non-inferior to insulin glargine U-100 for three-point MACE over a median follow-up of 2.0 years. [6] The pre-specified secondary endpoint of severe hypoglycemia showed a 40% reduction in favor of degludec (rate ratio 0.60, P<0.001), a finding with direct clinical and economic implications: severe hypoglycemia events generate emergency department visits averaging $1,387 per episode according to a 2019 JAMA Internal Medicine analysis. [16]

The BEGIN ONCE LONG trial (N=1,030) demonstrated that insulin degludec achieved A1C reductions comparable to insulin glargine U-100 with significantly less nocturnal hypoglycemia (rate ratio 0.68 to 95% CI 0.53, 0.87, P=0.002) in type 2 diabetes patients over 52 weeks. [17] The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy notes that "newer basal analogs with reduced hypoglycemia risk, including insulin degludec, are preferred when nocturnal or severe hypoglycemia is a clinical concern." [18]

A meta-analysis of eight phase 3 trials (Cochrane Library, updated 2021, N=6,947) comparing insulin degludec to insulin glargine found that degludec produced comparable A1C lowering with a 17% lower rate of confirmed hypoglycemia overall (rate ratio 0.83 to 95% CI 0.74, 0.94). [19] These data support the clinical argument made in Pennsylvania Medicaid prior-authorization requests when glargine has produced recurrent hypoglycemia.

Titrating and Managing Tresiba in Pennsylvania Patients

The FDA-approved starting dose for type 2 diabetes patients new to insulin is 10 units subcutaneously once daily, or 0.1 to 0.2 units/kg once daily. [4] Dose titration should target a fasting glucose of 80 to 130 mg/dL per the American Diabetes Association 2024 Standards of Care. [3]

Tresiba is injected subcutaneously in the abdomen, thigh, or upper arm. The flexible dosing interval is a clinically relevant feature: the minimum interval between injections is 8 hours, and the maximum gap tested in pharmacokinetic studies extended to 40 hours without loss of steady-state glucose control. [4] This flexibility allows patients with irregular schedules, a common real-world scenario in Pennsylvania's shift-worker and rural populations, to maintain consistent basal insulin coverage without the stricter same-time-each-day requirement of insulin glargine U-100.

Pennsylvania telehealth prescribers should document the injection site rotation plan, the hypoglycemia rescue protocol (glucagon prescription or glucagon nasal powder 3 mg), and the titration target in the visit note to support ongoing refills and potential future prior-authorization renewals. The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Diabetes Management Algorithm recommends reviewing basal insulin dose and titration at every diabetes visit and adjusting if fasting glucose remains above target for 3 consecutive days. [20]

Starting dose: 10 units once daily. Review in 3 days.